| Literature DB >> 25661519 |
Susanne Perkhofer1, Christoph Zenzmaier2, Emilie Frealle3, Michael Blatzer4, Hubert Hackl5, Bettina Sartori4, Cornelia Lass-Flörl4.
Abstract
Invasive aspergillosis is characterized by vascular invasion and thrombosis. In order to determine the antifungal activity of human platelets, hyphal elongation and metabolic activity of a clinical A. fumigatus isolate were measured. Genome-wide identification of differentially expressed genes in A. fumigatus was performed after exposure to platelets for 15, 30, 60 and 180 min. Data were analyzed by gene ontology annotation as well as functional categories (FunCat) and KEGG enrichment analyses. Platelets attenuated hyphal elongation and viability of A. fumigatus and in total 584 differentially expressed genes were identified, many of which were associated with regulation of biological processes, stress response, transport and metabolism. FunCat and KEGG enrichment analyses showed stress response and metabolic adaptation to be increased in response to platelets. Our findings demonstrate that A. fumigatus displayed a specific transcriptional response when exposed to platelets, thus reflecting their antifungal activities.Entities:
Keywords: Aspergillosis; Aspergillus fumigatus; Microarray; Platelets; Thrombocytes; Transcriptome
Mesh:
Substances:
Year: 2015 PMID: 25661519 PMCID: PMC4415150 DOI: 10.1016/j.ijmm.2015.01.002
Source DB: PubMed Journal: Int J Med Microbiol ISSN: 1438-4221 Impact factor: 3.473
Fig. 1Platelets impact on hyphal elongation and metabolic activity of A. fumigatus. (A) A. fumigatus was incubated for 16 h in the absence or presence of platelets at a platelets to conidia ratio of 100:1 prior to determination of hyphal elongation. Bars represent mean ± SEM of three independent experiments. Significance versus control (0) treatment is indicated (***p < 0.001). (B) Conidia were incubated for 16 h to procude hyphae and platelets were added for the times indicated. Thereafter hyphal damage was analysed by XTT assay and untreated platelets served as control. Antifungal activity was calculated as percentage of hyphal damage and bars represent mean ± SEM of three independent experiments. (C) Viable untreated A. fumigatus is characterized by green fluorescent hyphae with clearly red fluorescent vacuole structures in FUN-1 staining. (D) Exposure to platelets impaired A. fumigatus viability as shown by green fluorescent hyphae and lack of red fluorescent vacuole structures at sites of hyphal-platelet contact identified by light microscopy (E; arrows). (F) Amphotericin B-treated A. fumigatus showed no remaining red fluorescent vacuole structures.
Fig. 2Genes differentially expressed in Aspergillus fumigatus upon exposure to human platelets. Venn diagrams showing genes that are at least two-fold up- or down-regulated in A. fumigatus after 15 min, 30 min, 1 h or 3 h of exposure to platelets. Genes significantly differentially expressed at least at one time point were included.
Fig. 3Gene Ontology classification of differentially expressed genes. Genes differentially expressed (p < 0.05) once at any time point were annotated to GO slim terms in the GO Biological Process domain. Bars represent relative frequency of annotation to the single GO slim terms as percentage of annotated genes for each time point.
Second level FunCat Enrichment Analysis* of genes differentially expressed.
| 11.06 | RNA modification | 3 (6.56 × 10−3) | 3 (4.03 × 10−2) | 6 (7.10 × 10−3) | 3 (1.60 × 10−2) | ||||
| 11.04 | RNA processing | 6 (3.72 × 10−2) | 18 (3.51 × 10−4) | 25 (1.16 × 10−4) | 12 (1.18 × 10−4) | ||||
| 32.07 | Detoxification | 6 (3.10 × 10−2) | |||||||
| 02.13 | Respiration | 6 (9.29 × 10−3) | 11 (3.01 × 10−6) | ||||||
| 42.32 | Flagellum | 1 (1.17 × 10−2) | 1 (1.26 × 10−2) | ||||||
| 16.21 | Complex cofactor/cosubstrate/vitamine binding | 11 (1.72 × 10−2) | 14 (1.02 × 10−3) | ||||||
| 02.11 | Electron transport and membrane-associated energy conservation | 5 (2.18 × 10−2) | 9 (4.80 × 10−5) | ||||||
| 20.09 | Transport routes | 6 (2.90 × 10−2) | 10 (2.01 × 10−2) | 19 (3.61 × 10−2) | |||||
| 16.03 | Nucleic acid binding | 15 (4.29 × 10−2) | 3 (2.10 × 10−2) | 33 (3.14 × 10−3) | 13 (7.60 × 10−3) | ||||
| 16.25 | Oxygen binding | 1 (4.62 × 10−2) | 1 (4.95 × 10−2) | ||||||
| 01.05 | C-compound and carbohydrate metabolism | 12 (4.24 × 10−3) | 13 (2.20 × 10−6) | 18 (2.37 × 10−2) | |||||
| 20.01 | Transported compounds (substrates) | 12 (5.77 × 10−3) | 29 (1.13 × 10−3) | 24 (3.14 × 10−2) | |||||
| 01.01 | Amino acid metabolism | 17 (2.45 × 10−4) | |||||||
| 34.01 | Homeostasis | 9 (9.29 × 10−3) | |||||||
| 16.01 | Protein binding | 10 (1.49 × 10−2) | 54 (1.13 × 10−2) | 6 (3.09 × 10−2) | |||||
| 02.10 | Tricarboxylic-acid pathway | 3 (2.88 × 10−2) | |||||||
| 10.01 | DNA processing | 2 (3.05 × 10−2) | 28 (1.42 × 10−3) | ||||||
| 02.09 | Anaplerotic reactions | 1 (3.74 × 10−2) | |||||||
| 42.16 | Mitochondrion | 5 (4.11 × 10−2) | 4 (3.48 × 10−2) | ||||||
| 16.09 | Lipid binding | 3 (4.29 × 10−2) | |||||||
| 11.02 | RNA synthesis | 5 (4.76 × 10−2) | 2 (3.85 × 10−2) | ||||||
| 01.06 | Lipid, fatty acid and isoprenoid metabolism | 8 (2.13 × 10−3) | 1 (2.62 × 10−2) | ||||||
| 40.10 | Cell death | 10 (6.73 × 10−3) | |||||||
| 42.01 | Cell wall | 1 (1.51 × 10−2) | |||||||
| 12.07 | Translational control | 6 (1.98 × 10−2) | |||||||
| 16.17 | Metal binding | 27 (4.34 × 10−2) | |||||||
| 01.03 | Nucleotide/nucleoside/nucleobase metabolism | 9 (2.82 × 10−3) | |||||||
| 16.19 | Nucleotide/nucleoside/nucleobase binding | 14 (4.53 × 10−3) | |||||||
| 42.27 | Extracellular/secretion proteins | 2 (1.50 × 10−2) | |||||||
| 01.07 | Metabolism of vitamins, cofactors and prosthetic groups | 6 (4.58 × 10−2) | |||||||
p-value cutoff for enrichment analysis 0.05.
Third level FunCat Enrichment Analysis* of genes differentially expressed.
| 11.06.01 | rRNA modification | 2 (4.43 × 10−3) | 2 (1.65 × 10−2) | ||||||
| 20.01.21 | RNA transport | 3 (7.44 × 10−3) | 3 (4.51 × 10−2) | ||||||
| 14.13.04 | Lysosomal and vacuolar protein degradation | 2 (2.22 × 10−2) | 3 (1.27 × 10−2) | ||||||
| 01.03.16 | Polynucleotide degradation | 3 (2.70 × 10−2) | |||||||
| 16.03.03 | RNA binding | 5 (3.40 × 10−2) | 8 (2.67 × 10−2) | 8 (3.26 × 10−3) | |||||
| 32.07.07 | Oxygen and radical detoxification | 3 (6.28 × 10−3) | |||||||
| 12.04.03 | Translation termination | 1 (4.10 × 10−2) | |||||||
| 30.01.11 | Ligand-dependent nuclear receptors | 1 (4.10 × 10−2) | |||||||
| 16.21.08 | Fe/S binding | 5 (3.02 × 10−5) | 5 (4.29 × 10−6) | ||||||
| 02.11.05 | Accessory proteins of electron transport and membrane-associated energy conservation | 5 (2.45 × 10−4) | 6 (2.97 × 10−6) | ||||||
| 11.02.01 | rRNA synthesis | 5 (1.29 × 10−3) | 5 (2.47 × 10−4) | ||||||
| 02.13.03 | Aerobic respiration | 5 (3.54 × 10−3) | 8 (1.24 × 10−5) | ||||||
| 02.13.01 | Anaerobic respiration | 2 (4.64 × 10−3) | 2 (5.34 × 10−3) | ||||||
| 16.21.07 | NAD/NADP binding | 7 (7.91 × 10−3) | |||||||
| 20.01.15 | Electron transport | 9 (1.25 × 10−2) | 15 (8.57 × 10−6) | 6 (4.76 × 10−2) | |||||
| 01.03.01 | Purin nucleotide/nucleoside/nucleobase metabolism | 5 (1.83 × 10−2) | |||||||
| 01.20.01 | Metabolism of primary metabolic sugar derivatives | 2 (3.42 × 10−2) | |||||||
| 16.21.05 | FAD/FMN binding | 4 (4.54 × 10−2) | 5 (1.46 × 10−2) | ||||||
| 11.04.03 | mRNA processing (splicing, 5′-, 3′-end processing) | 13 (4.56 × 10−4) | 17 (3.67 × 10−4) | ||||||
| 11.04.02 | tRNA processing | 4 (2.05 × 10−2) | 7 (9.41 × 10−4) | 3 (1.29 × 10−2) | |||||
| 01.03.04 | Pyrimidine nucleotide/nucleoside/nucleobase metabolism | 4 (4.19 × 10−2) | |||||||
| 16.01.01 | Receptor binding | 2 (4.28 × 10−2) | |||||||
| 10.01.03 | DNA synthesis and replication | 6 (4.72 × 10−2) | 10 (6.14 × 10−3) | ||||||
| 01.01.05 | Metabolism of urea cycle, creatine and polyamines | 4 (1.82 × 10−3) | |||||||
| 34.01.01 | Homeostasis of cations | 8 (1.17 × 10−2) | |||||||
| 20.01.01 | Ion transport | 8 (1.56 × 10−2) | |||||||
| 01.20.36 | Non-ribosomal peptide synthesis | 2 (2.58 × 10−2) | |||||||
| 02.45.15 | Energy generation (e.g. ATP synthase) | 2 (3.08 × 10−2) | |||||||
| 16.03.01 | DNA binding | 1 (4.23 × 10−2) | 22 (3.16 × 10−3) | ||||||
| 01.01.11 | Metabolism of the pyruvate family (alanine, isoleucine, leucine, valine) and D-alanine | 3 (4.46 × 10−2) | |||||||
| 10.01.05 | DNA recombination and DNA repair | 17 (2.18 × 10−3) | |||||||
| 40.10.02 | Apoptosis (type I programmed cell death) | 10 (3.40 × 10−3) | |||||||
| 01.05.02 | Sugar, glucoside, polyol and carboxylate metabolism | 1 (4.87 × 10−3) | |||||||
| 11.06.02 | tRNA modification | 5 (6.32 × 10−3) | |||||||
| 14.07.07 | Modification by ubiquitin-related proteins | 5 (6.94 × 10−3) | |||||||
| 10.01.02 | DNA topology | 7 (7.87 × 10−3) | |||||||
| 01.05.03 | Polysaccharide metabolism | 1 (2.25 × 10−2) | |||||||
| 32.01.09 | DNA damage response | 8 (2.51 × 10−2) | |||||||
| 10.03.04 | Nuclear and chromosomal cycle | 7 (3.21 × 10−2) | |||||||
| 20.09.18 | Cellular import | 5 (4.21 × 10−2) | |||||||
| 16.19.03 | ATP binding | 24 (4.40 × 10−2) | 12 (3.04 × 10−3) | ||||||
| 01.20.31 | Metabolism of secondary products derived from L-lysine, L-arginine and L-histidine | 2 (4.48 × 10−2) | |||||||
| 14.13.01 | Cytoplasmic and nuclear protein degradation | 12 (4.60 × 10−2) | |||||||
| 11.04.01 | rRNA processing | 6 (4.11 × 10−3) | |||||||
| 01.01.09 | Metabolism of the cysteine – aromatic group | 5 (2.92 × 10−2) | |||||||
| 01.20.15 | Metabolism of derivatives of dehydroquinic acid, shikimic acid and chorismic acid | 2 (4.25 × 10−2) | |||||||
| 20.03.22 | Transport ATPases | 3 (4.74 × 10−2) | |||||||
| 32.07.01 | Detoxification involving cytochrome P450 | 3 (2.18 × 10−2) | |||||||
| 34.11.01 | Photoperception and response | 2 (2.34 × 10−2) | |||||||
| 01.25.09 | Extracellular lignin degradation | 1 (3.25 × 10−2) | |||||||
| 01.25.03 | Extracellular protein degradation | 1 (4.05 × 10−2) | |||||||
p-value cutoff for enrichment analysis 0.05
Third KEGG Enrichment Analysis* of genes differentially expressed.
| 1.1.15 | Inositol phosphate metabolism | 2 (1.44 × 10−3) | 3 (3.04 × 10−4) | ||||||
| 1.3.11 | Ether lipid metabolism | 1 (2.55 × 10−2) | |||||||
| 1.2.1 | Oxidative phosphorylation | 6 (9.49 × 10−4) | 8 (4.59 × 10−5) | ||||||
| 0.1.1 | Metabolic pathways | 22 (4.95 × 10−3) | 24 (1.55 × 10−2) | 12 (1.81 × 10−2) | |||||
| 1.4.1 | Purine metabolism | 4 (3.97 × 10−2) | 5 (1.04 × 10−3) | ||||||
| 2.1.3 | Spliceosome | 8 (2.88 × 10−5) | 9 (5.91 × 10−5) | ||||||
| 3.1.1 | ABC transporters | 1 (4.75 × 10−2) | 1 (3.03 × 10-2) | ||||||
| 1.6.1 | beta-Alanine metabolism | 3 (8.28 × 10−3) | |||||||
| 1.5.6 | Lysine biosynthesis | 2 (1.69 × 10−2) | |||||||
| 1.1.10 | Pyruvate metabolism | 3 (3.72 × 10−2) | |||||||
| 1.8.5 | Pantothenate and CoA biosynthesis | 2 (4.33 × 10−2) | |||||||
| 2.4.5 | Homologous recombination | 3 (5.79 × 10−3) | |||||||
| 2.4.1 | DNA replication | 3 (3.62 × 10−2) | |||||||
| 1.4.2 | Pyrimidine metabolism | 4 (4.81 × 10−2) | 4 (2.95 × 10−3) | ||||||
| 2.1.1 | RNA polymerase | 3 (1.79 × 10−3) | |||||||
| 1.5.13 | Phenylalanine, tyrosine and tryptophan biosynthesis | 2 (2.76 × 10−2) | |||||||
| 1.1.6 | Galactose metabolism | 2 (2.70 × 10−2) | |||||||
| 1.9.9 | Limonene and pinene degradation | 3 (4.51 × 10−2) | |||||||
p-value cutoff for enrichment analysis 0.05
List of Aspergillus fumigatus genes commonly identified by our study and by previous studies.
| Afu1g02610 | rRNA processing protein | −0.66 | −0.19 | −0.02 | ↑ | |||
| Afu1g09570 | Hypothetical protein | −0.11 | 0.68 | 0.1 | ↑ | |||
| Afu1g13370 | Aflatoxin B1-aldehyde reductase GliO-like | 0.71 | 0.45 | 0.84 | ↑ | |||
| Afu1g14550 | Mn superoxide dismutase MnSOD | −0.41 | −0.97 | −0.31 | ↑ | ↑ | ||
| Afu1g16550 | Dihydrouridine synthase family protein | −0.99 | −0.3 | 0.56 | ↑ | |||
| Afu2g02310 | Actin cortical patch protein Sur7 | −0.42 | −0.27 | 0.58 | ↑ | |||
| Afu2g03120 | Cell wall glucanase (Utr2) | −0.47 | −0.05 | −0.69 | ↑ | |||
| Afu2g07420 | Actin-bundling protein Sac6 | 0.21 | 0.54 | 0.88 | ↑ | |||
| Afu2g07500 | Prolidase pepP | −0.62 | 0.38 | ↑ | ||||
| Afu2g10330 | Hypothetical protein | −0.3 | −0.15 | ↑ | ||||
| Afu2g15960 | Nucleotide binding protein Nbp35 | 0.05 | 0.64 | 0.07 | ↑ | |||
| Afu2g16750 | Nonsense-mediated mRNA decay protein 3 | −0.58 | 0.56 | −0.87 | ↑ | |||
| Afu3g00810 | Cholestenol delta-isomerase | −0.75 | −0.46 | −0.48 | ↑ | |||
| Afu3g00850 | Hypothetical protein | −0.75 | −0.98 | −0.71 | ↑ | |||
| Afu3g01260 | Acetyltransferase, GNAT family family | 0 | −0.62 | ↓ | ||||
| Afu3g01580 | GMC oxidoreductase | −0.09 | 0.03 | ↑ | ||||
| Afu3g02270 | Mycelial catalase Cat1 | 3.41 | 0.17 | −0.31 | ↑ | |||
| Afu3g06070 | Histone H1 | −0.48 | 0.08 | ↑ | ||||
| Afu3g07850 | Pheromone maturation dipeptidyl aminopeptidase DapB | −0.69 | -0.62 | ↑ | ||||
| Afu3g07910 | UDP-glucose 4-epimerase | 0.76 | 0.49 | 0.21 | ↑ | |||
| Afu3g08110 | Cell wall protein | −0.32 | −0.84 | −0.07 | ↑ | |||
| Afu3g10770 | RTA1 domain protein | 0.14 | ↑ | |||||
| Afu4g01140 | MFS multidrug transporter | ↓ | ||||||
| Afu4g05900 | Hypothetical protein | −0.36 | 0.42 | −0.64 | ↑ | |||
| Afu4g10410 | Aspartate aminotransferase | 0.38 | −0.12 | −0.17 | ↑ | ↑ | ||
| Afu4g11130 | Hypothetical protein | 0.67 | ↑ | |||||
| Afu4g14250 | Hypothetical protein | -0.08 | 0.3 | ↓ | ||||
| Afu5g01740 | Deoxyhypusine synthase | −0.42 | −0.48 | −0.3 | ↑ | |||
| Afu5g02330 | Major allergen and cytotoxin AspF1 | −0.36 | −0.34 | ↓/↑ | ||||
| Afu5g03560 | Glutamyl-tRNA synthetase | 0.36 | 0.58 | 0.75 | ↑ | |||
| Afu5g05830 | CorA family metal ion transporter | −0.83 | −0.65 | −0.7 | ↑ | |||
| Afu6g03680 | Hypothetical protein | 0.69 | 0.2 | ↑ | ||||
| Afu6g13150 | Hypothetical protein | 0.84 | 0.22 | 0.85 | ↑ | |||
| Afu6g14090 | CFEM domain protein | −0.32 | −0.01 | ↑ | ||||
| Afu7g00580 | Hypothetical protein | −0.31 | 0.9 | ↑ | ||||
| Afu7g03830 | DNA repair protein Rad7, protein | 0.52 | 0.53 | ↑ | ||||
| Afu7g04290 | Amino acid permease (Gap1) | 0.6 | −0.39 | ↑ | ↑ | |||
| Afu8g05710 | MFS sugar transporter Stl1 | −0.09 | ↑ | ↑ | ||||
| Afu8g07130 | AhpC/TSA family thioredoxin peroxidase | 0.16 | 0.27 | ↑ | ↑ | |||
Log 2 relative fold change.
Sugui et al.
Immature dentritic cells, Morton et al.
Epithelial airway cells, Oosthuizen et al.; ↑…up-regulation; ↓…down-regulation.